Ironwood Pharma (IRWD) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update
February 15, 2018 8:01 AM ESTGenerated 2017 revenue of $298 million, driven primarily by LINZESS® (linaclotide) U.S. net sales of $701 million and expansion of LINZESS commercial margin to 61%
On track to advance key pipeline candidates in 2018, including Phase III trials for IW-3718 and LINZESS and Phase II trials for praliciguat (IW-1973) and IW-1701
Expect to generate positive cash flow in 4Q 2018 through continued top-line growth and financial discipline
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
